{
  "id": 19682300,
  "title": "Aquestive Therapeutics director buys $99,330 in shares",
  "url": "https://urgent.news/2026/11/12/aquestive-therapeutics-director-buys-99-330-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-12T17:30:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/aquestive-therapeutics-director-buys-99330-in-shares-93CH-5022879"
  },
  "original_language": "en",
  "account": "Richard J. Daly, a director at Aquestive Therapeutics, Inc., made a significant move in the company's stock on November 10, 2026. He bought approximately $99,330 worth of shares, purchasing 28,025 common shares. The price per share varied between $3.53 and $3.545, with Daly acquiring 1,200 shares at $3.53 each and 26,825 shares at $3.545 each. After these transactions, Daly now owns 28,025 shares of Aquestive Therapeutics common stock directly.\n\nThe purchase occurred as AQST shares were trading at $3.60, which represents a 44.6% decline year-to-date. This price is notably below the stock's 52-week high of $6.74, leading analysts to suggest that the stock may be overvalued at its current level. Despite this, analysts remain optimistic about the stock, setting price targets ranging from $6 to $11. Investors can also access 6 additional exclusive tips for AQST subscribers through InvestingPro.\n\nIn a separate development, Aquestive Therapeutics reported its Q3 2026 financial results, which fell short of Wall Street expectations. The company reported an adjusted loss of $0.18 per share, whereas analysts had forecast a loss of $0.12 per share. Revenue for the quarter was $7.5 million, compared to the expected $11.02 million. Despite these disappointing results, the company continues to advance its lead drug candidate toward a critical FDA decision. Aquestive expects to conclude the year with over $70 million in cash, a positive indicator for its financial standing.\n\nThese developments carry significant implications for the company's future financial performance. As the FDA decision on the lead drug candidate approaches, the financial community will be closely watching the situation. This article was produced with AI assistance and reviewed by an editor, ensuring accuracy and reliability.",
  "summary": null,
  "key_points": [
    "Richard J. Daly bought $99,330 worth of Aquestive Therapeutics shares on November 10, 2026.",
    "Daly acquired 28,025 shares at prices between $3.53 and $3.545 per share.",
    "Despite Q3 2026 results missing expectations, the company holds over $70 million in cash."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}